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Abstract
Purpose Congenital diaphragmatic hernia (CDH) is
characterized by a developmental defect in the diaphragm,
pulmonary hypoplasia and pulmonary hypertension.
NPAS3 is a PAS domain transcription factor regulating
Drosophila tracheogenesis. NPAS3 null mice develop
pulmonary hypoplasia in utero and die after birth due to
respiratory failure. We aimed to evaluate NPAS3 expres-
sion during normal and abnormal lung development due to
CDH.
Methods CDH was induced by administering 100 mg/ml
nitrofen to time-pregnant dams on embryonic day (E) 9 of
gestation. Lungs were isolated on E15, E18 and E21 and
NPAS3 localization was determined by immunohisto-
chemistry and quantified using Western blotting.
Results We found that only E21 hypoplastic CDH lungs
have reduced expression of NPAS3 in the terminal sac-
cules. Western blotting confirmed the down-regulation of
NPAS3 protein in the nitrofen-induced hypoplastic lungs.
Conclusions We demonstrate for the first time that ni-
trofen-induced hypoplastic CDH lungs have reduced
NPAS3 expression in the terminal saccules during the later
stages of abnormal lung development. Our findings suggest
that NPAS3 is associated with pulmonary hypoplasia in
CDH.
Keywords Congenital diaphragmatic hernia  Pulmonary
hypoplasia  Lung development  Nitrofen  NPAS3
Introduction
A developmental diaphragmatic defect characterizes con-
genital diaphragmatic hernia (CDH) and CDH is associated
with pulmonary hypoplasia and pulmonary hypertension.
Although it is relatively easy to repair the diaphragmatic
defect in newborns, the morbidity and mortality of CDH
patients remains high [1]. A better understanding of the
molecular mechanisms regulating lung development will
help to better understand abnormal lung development in
CDH and improve the outcome of babies with this devas-
tating disease [2–4].
NPAS3 is a neuronal PAS domain protein 3 gene that
encodes a basic helix–loop–helix (bHLH) transcription
factor that is expressed broadly in the developing neu-
roepithelium [5, 6]. Members of this protein family contain
a bHLH DNA binding domain located on the amino-ter-
minal side of a PAS domain. The PAS domain is ap-
proximately 260 amino acids in length, contains two direct
repeats of about 60 amino acids [7] and functions in diverse
physiological contexts including environmental adaptation
to hypoxia and circadian regulation [8]. NPAS3 regulates
Drosophila tracheogenesis and is associated with lung
development in vertebrates [9]. The human NPAS3 protein
is evolutionarily conserved among mammals, including the
mouse, rat and chimpanzee, by having more than 90 %
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conserved sequence identity in the peptide sequence [10].
There is only one study reporting the importance of NPAS3
for lung development: NPAS3 null mice develop pul-
monary hypoplasia in utero and die after birth from res-
piratory failure. Moreover, NPAS3 is essential for normal
lung development, playing a crucial role in maintaining
lung homeostasis and is also expressed and important for
postnatal lung pathologies [9]. Little is known about the
embryonic expression of the human NPAS3 gene [11].
NPAS3 has also been reported by others to be associated
with several disorders including schizophrenia, but most
work has focussed on the brain [12–17].
We hypothesized that abnormal NPAS3 expression un-
derlies abnormal lung development in CDH and, therefore,
we aimed to evaluate the expression of NPAS3 in normal
and abnormal CDH lungs in the nitrofen rat model of CDH.
Materials and methods
Animal experiments were performed and approved by the
Bannatyne Animal Care Committee of the University of
Manitoba. Animals were housed according to the recom-
mendations of NIH guidelines and the Guide for the Care
and Use of Laboratory Animals, published by the National
Academy Press [18, 19].
Animal and experimental design
Adult Sprague–Dawley female rats were mated overnight
and checked the following morning to confirm a vaginal
plug. Plug confirmation was considered embryonic day
zero (E0). On E9, randomly selected pregnant rats, re-
ceived either 100 mg of nitrofen (2,4-dichlorophenyl-p-
nitrophenylether) dissolved in 1 ml of olive oil, or olive oil
alone by orally gavaging them under a short anesthesia. On
E15, E18 and E21 dams were euthanized, and fetuses were
harvested by Cesarean section and killed by decapitation.
Lungs were dissected and divided into two groups (control
and hernia) from three different mothers for each gesta-
tional time point (n = 5 for each group). Lungs were then
either fixed in 4 % paraformaldehyde in PBS at 4 C
overnight for immunohistochemistry or snap frozen in
liquid nitrogen for Western blot analysis.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-embed-
ded lung tissues from different stages of lung development
as a qualitative method. Immunohistochemistry was carried
out on 5-lm sections. Tissue sections were deparaffinized
in xylene and rehydrated through a graded alcohol series.
Sections were incubated with the antibody for NPAS3
(ProSci incorporated, 4109) overnight at 4 C (1:1000 di-
lution) as previously described [20]. Negative control re-
actions were performed by omission of the primary
antibody. The secondary antibody was a horseradish per-
oxidase-labeled anti-rabbit antibody (Jackson Labs,
111-175-144) and this was applied for 1 h in a 1:400 di-
lution at room temperature. Sections were then developed
with a diaminobenzidine (DAB) H2O2 substrate complex
and counterstained with hematoxylin. Subsequently, the
sections were dehydrated, and the slides mounted with
glass coverslips. Results are representative of embryos
from three different mothers. Results were quantified in a
blinded fashion and confirmed by Western blot.
Western blot
Nitrofen and control lungs were washed and protein was
extracted using lysis buffer: 10 mM Tris–HCl (pH 6.8),
5 lM b-glycerophosphate, 20 lM EDTA, 5 % SDS, a
protease inhibitor cocktail tablet and phosphatase inhibitors
(1 mM sodium orthovanadate, 2 mM EGTA, 10 mM
sodium pyrophosphate, 30 mM sodium chloride). Protein
concentration was determined using RC DCTM Protein
Assay (Bio-Rad). Fifteen lg of total proteins were reduced
with b-mercaptoethanol, size fractionated by SDS-PAGE
and transferred to a nitrocellulose membrane (Bio-Rad).
NPAS3 was detected with an NPAS3 antibody (ProSci in-
corporated) using a 1:1000 dilution and a horseradish
peroxidase-conjugated goat-anti-rabbit secondary antibody
(Bio-Rad) in a 1:5000 dilution. For loading control, blots
were probed with anti-GAPDH (Abcam, MA, USA) in a
1:10000 dilution, using a horseradish peroxidase-conju-
gated goat-anti-mouse secondary antibody in a 1:6000 di-
lution (Bio-Rad). Exposed films were scanned and
densitometry was performed using ImageJ software
(Wayne Rasband, NIH, USA).
Statistical analysis
All quantitative data are presented as mean ± standard
error. Differences between control lungs and hypoplastic
CDH lungs at each gestational time point were evaluated
using one-way-ANOVA Bonferroni test. Statistical sig-
nificance was set at p\ 0.05.
Immunohistochemistry studies
NPAS3 protein was present at all gestational time points
(E15, E18 and E21) in control and nitrofen-induced hy-
poplastic lungs. At E15 and E18, NPAS3 expression was
similar between control and hypoplastic CDH lungs
(Fig. 1a, b). NPAS3 protein was expressed in the airway
epithelium and mesothelium as well as in the mesenchymal
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Fig. 1 NPAS3 expression in
normal and nitrofen-induced
hypoplastic lungs during fetal
rat lung development. NPAS3 is
present throughout all stages of
lung development from early
E15 until late E21. a E15.
b E18. c E21.
d Immunohistochemistry
negative control—omission of
the primary antibody
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cells. NPAS3 is mainly nuclear. In E21 CDH lungs, NPAS3
was lower in the peribronchial mesenchymal cells and in
the mesenchyme (Fig. 1c).
Western blot studies
We quantified NPAS3 expression levels using Western
blot. Western blot analysis was in agreement with IHC
observations and revealed that NPAS3 was expressed
throughout all studied gestational ages in normal and CDH
fetal lungs. NPAS3 expression was similar between normal
and CDH lungs on E15 and E18 (early and late pseudog-
landular stage, respectively, Fig. 2a, b) and lower on E21
(saccular stage) in CDH lungs when compared to controls
(Fig. 2c).
Discussion
As NPAS3 is important for lung development and growth,
we aimed to evaluate if NPAS3 expression is different in
nitrofen-induced hypoplastic CDH lungs, to determine
whether this protein is associated with abnormal lung de-
velopment and CDH. If that is the case it will help to better
understand the disease and address the mechanisms in-
volved in hypoplastic lung development. We observed that
NPAS3 expression is similar during the earlier stages of
lung development in normal and nitrofen-induced CDH
lungs. In contrast, NPAS3 expression was decreased in
CDH lungs prior to birth suggesting that NPAS3 plays a
role during the later stages of lung development. These
findings are supported by published data from others
demonstrating that NPAS3 is not only a regulator of
proximal lung development, but also appears to play a role
during postnatal lung pathology. Moreover, in normal lung
development, FGF-10 induces the dynamic expression of
its inhibitor Spry2 and FGF-10 expression decreases [21].
Furthermore, exogenous administration of FGF10 in
NPAS3 knockout mice, rescues abnormal lung branching
[9]. The mechanism by which NPAS3 controls lung de-
velopment is complex, although FGF10 seems to be asso-
ciated with the regulation of NPAS3 expression.
NPAS3 knockout mice have reduced branching mor-
phogenesis early in gestation with diminished alveolariza-
tion, decreased Shh, FGF9, FGF10 and Bmp4 and
increased Spry2 consistent with reduced FGF signaling,
resulting in death due to respiratory distress after birth.
Hypoplastic CDH lungs also display abnormal branching
morphogenesis. However, in our current study we observed
normal NPAS3 expression during the early stages of lung
development when normal and nitrofen-induced hy-
poplastic CDH lungs were compared (Fig. 1a, b) [19].
These data suggest that NPAS3 does not play a key role
during the abnormal branching morphogenesis of nitrofen-
induced hypoplastic CDH lungs. This might be due to CDH
being a multifactorial disease or that the mechanism by
which NPAS3 controls lung development is more complex
[9]. Moreover, NPAS3 heterozygous knockout mice do not
display reduced branching morphogenesis [9]. We are the
first to report a reduction of NPAS3 expression during the
saccular stages of nitrofen-induced abnormal lung devel-
opment. This suggests that in the nitrofen model, NPAS3
can be a regulator of late abnormal lung development in-
terfering with different signaling pathways.
It would be interesting in future studies using NPAS3
knockout mice, to investigate if retinoic acid, Bmp, and or
Shh exogenous administration will rescue abnormal
branching and lung growth. This experiment will demon-
strate if NPAS3 expression is mediated through any of
these signaling pathways that are known to be involved in
lung branching [19, 21–24].
NPAS3 expression is reduced in the mesenchymal cells
of the nitrofen-induced hypoplastic CDH lung and we did
not observe any expression in the peribronchial mes-
enchyme (Fig. 1c). Previous studies observed that NPAS3
heterozygous mice at the saccular stage of lung
Fig. 2 NPAS3 is lower in nitrofen-induced hypoplastic CDH lungs
during the later stages of fetal rat lung development. Western blot
analysis of NPAS3 performed in several gestational ages from E15 to
E21. Representative blot examples are shown. All protein levels were
normalized to GAPDH. a E15. b E18. c E21. Values represent
mean ± SE. p\ 0.05
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development have widespread defects in alveolar septation.
NPAS3 knockout mice are more severely affected with
only patches of future alveolar tissue interspersed with
dilated airways resulting in bronchiectasis [9].
In summary, we found that NPAS3 expression is lower
during the saccular stages of nitrofen-induced abnormal
lung development. Our findings suggest that abnormal
NPAS3 expression is associated with pulmonary hy-
poplasia in CDH.
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